Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Inclusion Criteria:

Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

Recurrent disease after platinum-based chemotherapy

Must have experienced disease persistence during primary platinum-based therapy or recurrence within 12 months after completion of platinum-based chemotherapy ("platinum-refractory" or "platinum-resistant" disease)

A patient receiving a second course of platinum-based chemotherapy for platinum-sensitive disease who then develops persistence or recurrence within 12 months is considered eligible for this trial
Must have measurable disease by RECIST criteria (phase II) (phase II closed as of 1/7/2011)

Must have received ≥ 1 prior platinum-based cytotoxic chemotherapy regimen (for primary disease) containing carboplatin, cisplatin, or other organoplatinum compound

Initial treatment may have included any of the following:

High-dose therapy
Consolidation therapy
Intraperitoneal (IP) therapy
Extended therapy administered after surgical or nonsurgical assessment
One additional non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule inhibitors) for recurrent or persistent disease allowed
Patients may have received hormonal therapy for management of disease (e.g., SERMs, aromatase inhibitors, progestins, and GnRH agonists)
No loculated ascites for which IP distribution of virus is not expected to be feasible
No known brain metastases
GOG performance status (PS) 0-2 (Karnofsky PS 60-100%)
Life expectancy > 12 weeks
Leukocytes ≥ 3,000/mcL
Absolute neutrophil count ≥ 1,500/mcL
Hemoglobin ≥ 10 g/dL
Platelets ≥ 100,000/mcL
Total bilirubin normal
AST/ALT ≤ 2.5 times upper limit of normal
Creatinine normal
Ejection fraction > 50% by echocardiogram or MUGA
Cardiac enzymes normal
Not pregnant or nursing
Fertile patients must use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
Must be able to avoid direct contact with pregnant or nursing women, infants, or immunocompromised individuals while on study and for ≥ 3 weeks following the last dose of study agent administration
Cardiac conduction abnormalities (e.g., bundle branch block, heart block) are allowed if their cardiac status has been stable for 6 months before study entry
At least 4 weeks since most recent cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C)
Recovered from adverse events due to agents administered more than 4 weeks earlier
No prior radiotherapy to the abdomen or pelvis
No other concurrent investigational agents
No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy

Exclusion Criteria:

Patients in whom insertion of an IP catheter is not feasible due to surgical contraindications or abdominal and pelvic adhesions
Known HIV infection or hepatitis B or C

Clinically significant cardiac disease (New York Heart Association class III or IV cardiac disease) including any of the following:

Pre-existing arrhythmia
Uncontrolled angina pectoris
Myocardial infarction 1 year prior to study entry
Compromised left ventricular ejection fraction ≥ grade 2 by MUGA or echocardiogram
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements

Chronic oral steroids at an equivalent dose of prednisone 5 mg daily

Inhaled steroids allowed
Patients on immunosuppressive therapy
Concurrent routine prophylactic use of growth factor (filgrastim [G-CSF] or sargramostim [GM-CSF])